Pharmacological treatment of adolescent psychiatric disorders.
Psychopharmacological treatments of major psychiatric disorders during adolescence, including depression, anxiety disorders, schizophrenia, and attention-deficit disorder, are reviewed. Pharmacokinetic and psychological aspects specific to adolescence, which if ignored may impair or abolish drug efficacy, are examined. Recommendations are given for safe use of tricyclic antidepressants, monoamine oxidase inhibitors, and neuroleptics in this age group. Areas where future research is needed to make rational pharmacological choices are noted.
D000293:Adolescent; D000294:Adolescent Behavior; D000929:Antidepressive Agents, Tricyclic / Q000627:therapeutic use; D001008:Anxiety Disorders / Q000188:drug therapy; D001289:Attention Deficit Disorder with Hyperactivity / Q000188:drug therapy; D002653:Child Behavior Disorders / Q000188:drug therapy*; D003866:Depressive Disorder / Q000188:drug therapy; D006801:Humans; D008094:Lithium / Q000627:therapeutic use; D016651:Lithium Carbonate; D001523:Mental Disorders / Q000188:drug therapy*; D008996:Monoamine Oxidase Inhibitors / Q000627:therapeutic use; D012559:Schizophrenia / Q000188:drug therapy
D000929:Antidepressive Agents, Tricyclic; D008996:Monoamine Oxidase Inhibitors; D016651:Lithium Carbonate; D008094:Lithium